Biocon Stock Forecast for 2023 - 2025 - 2030
Updated on 03/29/2024
Biocon Stock Forecast and Price Target
According to fourteen experts, who recently provided their 2024 price targets for Biocon, the average price target is Rp285.00, with a high estimate of Rp355.00 and a low estimate of Rp200.00. That is a potential upside of approximately 2.08% from the last closing price of Rp279.20 on March, 2024. Even if you are not interested in BIOCON stock, you should be aware of its competitors and their current standings.
2.08% Upside
Biocon Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Biocon's Price has fallen from Rp389.02 to Rp140.26 – a 63.95% decrease. In the next year, analysts believe that Fair Value will reach Rp385.05 – an increase of 174.53%. For the next seven years, the forecast is for Fair Value to grow by 488.55%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$599.43 | Buy/Sell | $591.94 | 0.10% |
ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF242.00 | Buy/Sell | CHF307.83 | 11.57% |
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$414.47 | Buy/Sell | $457.59 | 8.57% |
CSL Stock Forecast | CSL | Outperform |
12
|
$281.20 | Buy/Sell | $205.51 | -27.94% |
Biocon Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Biocon's Revenue has grown, rising from Rp63.67B to Rp111.74B – a growth of 75.50%. In the next year, analysts believe that Revenue will reach Rp147.10B – an increase of 31.64%. For the next seven years, the forecast is for Revenue to grow by 79.79%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BIIB Stock Forecast | Biogen | Outperform |
10
|
$230.07 | Buy/Sell | $299.62 | 29.09% |
ILMN Stock Forecast | Illumina | Outperform |
16
|
$139.06 | Buy/Sell | $159.28 | 7.87% |
CIPLA Stock Forecast | Cipla | Outperform |
18
|
Rp1.50k | Buy/Sell | Rp1.43k | -1.93% |
Biocon Dividend per Share Forecast for 2023 - 2025 - 2030
Biocon's Dividend per Share has grown In the last year, rising from Rp0.50 to Rp1.50 – a growth of 200.00%. In the following year, 18 experts forecast that Biocon's Dividend per Share will decrease by 23.33%, to Rp1.15. For the next seven years, experts predict that Biocon's Dividend per Share will grow at a rate of 17.23%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.97 | Buy/Sell | $11.73 | 0.25% |
500124 Stock Forecast | Dr. Reddy's Laboratories | Hold |
18
|
Rp6.38k | Buy/Sell | Rp5.67k | -6.20% |
AKZA Stock Forecast | Akzo Nobel N.V. | Outperform |
18
|
65.98€ | Buy/Sell | 79.42€ | 15.19% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ZYDUSLIFE Stock Forecast | Zydus Lifesciences | Outperform |
18
|
Rp994.45 | Buy/Sell | Rp655.25 | -15.53% |
DIVISLAB Stock Forecast | Divi's Laboratories | Underperform |
18
|
Rp3.60k | Buy/Sell | Rp3.30k | -7.55% |
500420 Stock Forecast | Torrent Pharmaceuticals | Outperform |
18
|
Rp2.70k | Buy/Sell | Rp2.13k | 3.82% |
Biocon EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Biocon's EBITDA has grown by 66.63%, rising from Rp15.94B to Rp26.57B. For the next year, analysts predict that EBITDA will reach Rp33.06B – an increase of 24.42%. Over the next seven years, experts believe that Biocon's EBITDA will grow at a rate of 79.75%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
500257 Stock Forecast | Lupin | Hold |
12
|
Rp1.67k | Buy/Sell | Rp1.11k | -8.05% |
ALKEM Stock Forecast | Alkem Laboratories | Hold |
18
|
Rp5.16k | Buy/Sell | Rp4.03k | 5.58% |
AUROPHARMA Stock Forecast | Aurobindo Pharma | Outperform |
18
|
Rp1.06k | Buy/Sell | Rp1.09k | 10.08% |
Biocon EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Biocon's EBIT has grown, moving from Rp10.52B to Rp15.64B – an increase of 48.70%. In the next year, analysts predict that EBIT will jump to Rp18.08B – up 15.56% from the current level. Looking ahead to seven years, experts forecast that EBIT will grow by 106.87%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£19.10 | Buy/Sell | £28.11 | 55.34% |
GRF Stock Forecast | Grifols | Outperform |
18
|
8.48€ | Buy/Sell | 18.48€ | 116.98% |
SOLB Stock Forecast | Solvay | Outperform |
17
|
24.10€ | Buy/Sell | 125.53€ | 18.26% |
Biocon EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Biocon's EPS has fallen from Rp5.88 to Rp2.12 – a 63.95% decrease. In the next year, analysts believe that EPS will reach Rp5.82 – an increase of 174.53%. For the next seven years, the forecast is for EPS to grow by 488.55%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
SDF Stock Forecast | K+S | Outperform |
8
|
13.52€ | Buy/Sell | 18.21€ | 22.41% |
500302 Stock Forecast | Piramal Enterprises | Hold |
18
|
Rp868.85 | Buy/Sell | Rp1.11k | 15.09% |
530019 Stock Forecast | Jubilant Pharmova | - |
18
|
Rp619.85 | Buy/Sell | Rp868.67 | -100.00% |